Results 71 to 80 of about 34,942 (245)

Pharmacogenomics in osteoporosis: Steps toward personalized medicine [PDF]

open access: yes, 2009
Robert Greene1, Shaymaa S Mousa, Mohamed Ardawi2, Mohamed Qari2, Shaker A Mousa11The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Center of Excellence in Osteoporosis Research, King Abdul Aziz ...
Mohamed Ardawi   +3 more
core  

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

open access: yesJournal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana   +7 more
doaj  

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo   +12 more
wiley   +1 more source

Pharmacogenomics of sickle cell disease: steps toward personalized medicine [PDF]

open access: yes, 2017
Marium Husain,1 Amber D Hartman,2 Payal Desai3 1Division of Medical Oncology, 2Division of Palliative Medicine, 3Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Sickle cell disease (SCD) is a ...
Desai P, Hartman AD, Husain M
core  

Practical recommendations for pharmacogenomics - based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics [PDF]

open access: yes, 2011
The present article summarizes the discussions of the 3rd European Science Foundation University of Barcelona (ESF-UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain.
Ron HN van Schaik   +39 more
core   +1 more source

Building a Pharmacogenomics Knowledge Model Toward Precision Medicine: Case Study in Melanoma

open access: yesJMIR Medical Informatics, 2020
BackgroundMany drugs do not work the same way for everyone owing to distinctions in their genes. Pharmacogenomics (PGx) aims to understand how genetic variants influence drug efficacy and toxicity.
Kang, Hongyu   +4 more
doaj   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes   +4 more
wiley   +1 more source

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott   +16 more
wiley   +1 more source

Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community

open access: yesClinical and Translational Science
Pharmacogenomics research has predominantly focused on populations of European ancestry, limiting the application to diverse populations such as American Indian and Alaska Native (AIAN) communities.
Madeline L. Wichman   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy